---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-096113"
form_type: "8-K"
ticker: "RAPH"
cik: "0001415397"
company_name: "Raphael Pharmaceutical Inc."
filed_at: "2026-09-01T16:51:41+00:00"
generated_at: "2026-09-01T16:53:10.217098+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Raphael Pharmaceutical signs 12-month AI transformation deal with AIcreatesAI for $180K

## Summary
- Agreement effective July 30, 2026; AIcreatesAI serves as managed AI transformation, commercialization, and growth partner for 12 months.
- Annual fee of $180,000 payable in $15,000 monthly installments; unpaid invoices defer until financing, capital, or revenues arrive.
- Company may issue common shares to satisfy deferred payments with AIcreatesAI's written consent, subject to securities laws and OTC Markets rules.
- AIcreatesAI entitled to 2% of net profits from any company-branded digital token platform, separate from the service fee and subject to board approval.
- Services include website/app/CRM development, marketing, research intelligence, partnership development, and investor communications.

## SEC filing metadata
- accession: 0001213900-26-096113
- form_type: 8-K
- ticker: RAPH
- cik: 0001415397
- company_name: Raphael Pharmaceutical Inc.
- filed_at: 2026-09-01T16:51:41+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1415397/000121390026096113/0001213900-26-096113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1415397/000121390026096113/ea0304182-8k_raphael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-096113
- JSON: https://secwatch.observer/filing/0001213900-26-096113.json
- Plain text: https://secwatch.observer/filing/0001213900-26-096113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.